Quiana Cooper
Psychiatric/Mental Health · Riverside, CANPI 1265052047
Payments from drug & device makers
Across 284 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$917
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$860
- AbbVie$498
- Otsuka America Pharmaceutical, Inc.$466
- Neurocrine Biosciences, Inc.$435
- Vanda Pharmaceuticals Inc.$362
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,162100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$243
- INVEGA TRINZA$243
- CAPLYTA$125
- VRAYLAR$101
How this compares
$6,163 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $185,376 |
| Buspirone Hcl | 17 | $233 |
| Quetiapine Fumarate | 16 | $230 |
| Guanfacine Hcl | 11 | $194 |
| Clonazepam | 12 | $132 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $112 |
| Citalopram HbrCitalopram Hydrobromide | 30 | $102 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $435 | $185,37623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Riverside
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.